Warsaw, Indiana-based Zimmer Biomet Holdings, Inc. (ZBH) operates worldwide as a medical technology company. The company has a market cap of $18.8 billion and designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma, among others. ZBH is expected to release its Q3 2026 earnings on Wednesday, November 4, 2026, before the market opens.
Ahead of the event, analysts expect the company’s EPS to be $1.89 on a diluted basis, down marginally from $1.90 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters, which is impressive.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts project the company’s EPS to be $8.54, up 4.2% from $8.20 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 5.2% year over year (YoY) to $8.98 in fiscal 2027.
www.barchart.comZBH stock has declined 5% over the past 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 14.4% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 24.2% rise during the same time frame.
www.barchart.comZBH’s sales trends have been underwhelming over the last five years, as its 4.4% annual growth came under the average for the healthcare sector. Moreover, the company’s annual earnings per share growth over the last five years has been 2.4%, which lagged its revenue gains, leading to less profitable incremental sales. ZBH’s returns on capital have also been below average, showcasing the lack of compelling investment opportunities.
Analysts are somewhat bullish on ZBH, with the stock having a “Moderate Buy” rating overall. Among the 29 analysts covering the stock, seven are recommending a “Strong Buy,” one suggests a “Moderate Buy,” 20 recommend a “Hold,” and one suggests a “Strong Sell.” ZBH’s average analyst price target of $105.29 indicates a 6.6% upside from current levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.